InMed Pharmaceuticals Ownership 2024 | Who Owns InMed Pharmaceuticals Now?


OverviewRevenueFinancialsChart

Institutional Ownership

8.60%

Insider Ownership

0.58%

Retail Ownership

90.81%

Institutional Holders

16.00

InMed Pharmaceuticals Institutional Shareholders


Institutional Shareholders by % of Total Shares

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
SABBY MANAGEMENT, LLC4.54%0.08%361,728-150,206-29.34%131,669Mar 31, 2024
ARMISTICE CAPITAL, LLC3.35%0.00%266,96861,00029.62%97,176Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC0.35%-28,300-10,600-27.25%10,000Mar 31, 2024
TWO SIGMA SECURITIES, LLC0.19%0.00%15,4232,52919.61%5,614Mar 31, 2024
CITADEL ADVISORS LLC0.16%-12,725-21,284-62.58%4,479Mar 31, 2024
BFSG, LLC0.00%-200200100.00%73,000Mar 31, 2024
QUBE RESEARCH & TECHNOLOGIES LTD0.00%-200--70Mar 31, 2024
BANK OF AMERICA CORP /DE/0.00%-100--36,000Mar 31, 2024
ADVISORNET FINANCIAL, INC0.00%-8080100.00%29,000Mar 31, 2024
ADVISOR GROUP HOLDINGS, INC.0.00%-41--13,000Mar 31, 2024
UBS GROUP AG0.00%-4141100.00%15Mar 31, 2024
ALLSQUARE WEALTH MANAGEMENT LLC0.00%-21--8Mar 31, 2024
0.00%-1919100.00%7Mar 31, 2024
NATIONAL BANK OF CANADA /FI/0.00%-12--3Mar 31, 2024
GLOBAL RETIREMENT PARTNERS, LLC0.00%-6--2,000Mar 31, 2024
TORONTO DOMINION BANK--2--1Mar 31, 2024
ADVISORY SERVICES NETWORK, LLC----59-100.00%-Mar 31, 2024
TD WATERHOUSE CANADA INC.----85-100.00%-Mar 31, 2024

InMed Pharmaceuticals's largest institutional shareholder is SABBY MANAGEMENT, LLC, holding 4.54% of the company's total share outstanding, currently valued at $131.67K. The top 10 institutional shareholders own together 8.60% of the company.

Institutional Shareholders by % of Total Assets

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
SABBY MANAGEMENT, LLC4.54%0.08%361,728-150,206-29.34%131,669Mar 31, 2024
ARMISTICE CAPITAL, LLC3.35%0.00%266,96861,00029.62%97,176Mar 31, 2024
TWO SIGMA SECURITIES, LLC0.19%0.00%15,4232,52919.61%5,614Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC0.35%-28,300-10,600-27.25%10,000Mar 31, 2024
BFSG, LLC0.00%-200200100.00%73,000Mar 31, 2024
ALLSQUARE WEALTH MANAGEMENT LLC0.00%-21--8Mar 31, 2024
ADVISORNET FINANCIAL, INC0.00%-8080100.00%29,000Mar 31, 2024
CITADEL ADVISORS LLC0.16%-12,725-21,284-62.58%4,479Mar 31, 2024
QUBE RESEARCH & TECHNOLOGIES LTD0.00%-200--70Mar 31, 2024
GLOBAL RETIREMENT PARTNERS, LLC0.00%-6--2,000Mar 31, 2024
0.00%-1919100.00%7Mar 31, 2024
ADVISOR GROUP HOLDINGS, INC.0.00%-41--13,000Mar 31, 2024
NATIONAL BANK OF CANADA /FI/0.00%-12--3Mar 31, 2024
UBS GROUP AG0.00%-4141100.00%15Mar 31, 2024
BANK OF AMERICA CORP /DE/0.00%-100--36,000Mar 31, 2024
TORONTO DOMINION BANK--2--1Mar 31, 2024
ADVISORY SERVICES NETWORK, LLC----59-100.00%-Mar 31, 2024
TD WATERHOUSE CANADA INC.----85-100.00%-Mar 31, 2024

The largest InMed Pharmaceuticals shareholder by % of total assets is SABBY MANAGEMENT, LLC. The company owns 361.73K shares of InMed Pharmaceuticals (INM), representing 0.08% of its total assets.

Institutional Buyers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
ARMISTICE CAPITAL, LLC3.35%0.00%266,96861,00029.62%97,176Mar 31, 2024
TWO SIGMA SECURITIES, LLC0.19%0.00%15,4232,52919.61%5,614Mar 31, 2024
BFSG, LLC0.00%-200200100.00%73,000Mar 31, 2024
ADVISORNET FINANCIAL, INC0.00%-8080100.00%29,000Mar 31, 2024
UBS GROUP AG0.00%-4141100.00%15Mar 31, 2024
0.00%-1919100.00%7Mar 31, 2024
TORONTO DOMINION BANK--2--1Mar 31, 2024
BANK OF AMERICA CORP /DE/0.00%-100--36,000Mar 31, 2024
NATIONAL BANK OF CANADA /FI/0.00%-12--3Mar 31, 2024
ADVISOR GROUP HOLDINGS, INC.0.00%-41--13,000Mar 31, 2024
GLOBAL RETIREMENT PARTNERS, LLC0.00%-6--2,000Mar 31, 2024
QUBE RESEARCH & TECHNOLOGIES LTD0.00%-200--70Mar 31, 2024
ALLSQUARE WEALTH MANAGEMENT LLC0.00%-21--8Mar 31, 2024
ADVISORY SERVICES NETWORK, LLC----59-100.00%-Mar 31, 2024
TD WATERHOUSE CANADA INC.----85-100.00%-Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC0.35%-28,300-10,600-27.25%10,000Mar 31, 2024
CITADEL ADVISORS LLC0.16%-12,725-21,284-62.58%4,479Mar 31, 2024
SABBY MANAGEMENT, LLC4.54%0.08%361,728-150,206-29.34%131,669Mar 31, 2024

As of Mar 31 2024, InMed Pharmaceuticals's largest institutional buyer is ARMISTICE CAPITAL, LLC. The company purchased 61.00K stocks of INM, valued at $97.18K.

Institutional Sellers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
SABBY MANAGEMENT, LLC4.54%0.08%361,728-150,206-29.34%131,669Mar 31, 2024
CITADEL ADVISORS LLC0.16%-12,725-21,284-62.58%4,479Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC0.35%-28,300-10,600-27.25%10,000Mar 31, 2024
TD WATERHOUSE CANADA INC.----85-100.00%-Mar 31, 2024
ADVISORY SERVICES NETWORK, LLC----59-100.00%-Mar 31, 2024
ALLSQUARE WEALTH MANAGEMENT LLC0.00%-21--8Mar 31, 2024
QUBE RESEARCH & TECHNOLOGIES LTD0.00%-200--70Mar 31, 2024
GLOBAL RETIREMENT PARTNERS, LLC0.00%-6--2,000Mar 31, 2024
ADVISOR GROUP HOLDINGS, INC.0.00%-41--13,000Mar 31, 2024
NATIONAL BANK OF CANADA /FI/0.00%-12--3Mar 31, 2024
BANK OF AMERICA CORP /DE/0.00%-100--36,000Mar 31, 2024
TORONTO DOMINION BANK--2--1Mar 31, 2024
0.00%-1919100.00%7Mar 31, 2024
UBS GROUP AG0.00%-4141100.00%15Mar 31, 2024
ADVISORNET FINANCIAL, INC0.00%-8080100.00%29,000Mar 31, 2024
BFSG, LLC0.00%-200200100.00%73,000Mar 31, 2024
TWO SIGMA SECURITIES, LLC0.19%0.00%15,4232,52919.61%5,614Mar 31, 2024
ARMISTICE CAPITAL, LLC3.35%0.00%266,96861,00029.62%97,176Mar 31, 2024

As of Mar 31 2024, InMed Pharmaceuticals's biggest institutional seller is SABBY MANAGEMENT, LLC. The company sold -0.15M shares of INM, valued at $131.67K.

Institutional New positions

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
BFSG, LLC0.00%-200200100.00%73,000Mar 31, 2024
ADVISORNET FINANCIAL, INC0.00%-8080100.00%29,000Mar 31, 2024
0.00%-1919100.00%7Mar 31, 2024

InMed Pharmaceuticals's largest new institutional shareholder by number of shares is BFSG, LLC, purchased 200.00 shares, valued at $73.00K, as of undefined.

Institutional Sold Out

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
TD WATERHOUSE CANADA INC.----85-100.00%-Mar 31, 2024
ADVISORY SERVICES NETWORK, LLC----59-100.00%-Mar 31, 2024

InMed Pharmaceuticals's largest sold out institutional shareholder by shares sold is TD WATERHOUSE CANADA INC., sold -85.00 shares, valued at -, as of undefined.

InMed Pharmaceuticals Mutual Fund Holders


Name% Total AssetsTotal SharesChange AmountChange %Date
FIDELITY CONCORD STREET TRUST0.00%13,905--Feb 29, 2024
FIDELITY CONCORD STREET TRUST0.00%556--Feb 29, 2024

InMed Pharmaceuticals's largest mutual fund holder by % of total assets is "FIDELITY CONCORD STREET TRUST", owning 13.90K shares, compromising 0.00% of its total assets.

InMed Pharmaceuticals Institutional Ownership Trends


Institutional Holdings Trend

DateHoldingsChange %
31 Mar, 241614.29%
31 Dec, 2314100.00%
30 Sep, 23716.67%
30 Jun, 236-45.45%
31 Mar, 2311-
31 Dec, 221137.50%
30 Sep, 228-

As of 31 Mar 24, 16 institutions are holding InMed Pharmaceuticals's shares, representing an increase of 14.29% compared to the previous quarter.

Shares Outstanding Trend

DateShares OutstandingChange %
31 Mar, 24685,866-14.72%
31 Dec, 23804,231310413.90%
30 Sep, 23259-87.33%
30 Jun, 232,044-97.51%
31 Mar, 2382,165-29.10%
31 Dec, 22115,894-12.90%
30 Sep, 22133,059-

InMed Pharmaceuticals (INM) has 685.87K shares outstanding as of 31 Mar 24, down -14.72% compared to the previous quarter.

Institutional Ownership Trend

DateOwnership %Change %
31 Mar, 248.60%8.46%
31 Dec, 2310.09%8995405.66%
30 Sep, 230.01%280.46%
30 Jun, 230.06%1.01%
31 Mar, 232.47%9.73%
31 Dec, 225.04%15.06%
30 Sep, 225.78%-

As of 31 Mar 24, InMed Pharmaceuticals is held by 8.60% institutional shareholders, representing a 8.46% growth compared to 31 Dec 23.

Institutional Increased Positions Trend

DateIncreased PositionsChange %
31 Mar, 246-33.33%
31 Dec, 23980.00%
30 Sep, 235150.00%
30 Jun, 232-60.00%
31 Mar, 235-37.50%
31 Dec, 228-
30 Sep, 228-

6 institutional shareholders have increased their position in INM stock as of 31 Mar 24 compared to 9 in the previous quarter (a -33.33% decrease).

Institutional Reduced Positions Trend

DateReduced PositionsChange %
31 Mar, 24350.00%
31 Dec, 232-
30 Sep, 23--
30 Jun, 23--
31 Mar, 23--100.00%
31 Dec, 222-
30 Sep, 22--

3 institutional shareholders have reduced their position in INM stock as of 31 Mar 24 compared to 2 in the previous quarter (a 50.00% increase).

All Institutional Ownership Trend Data

DateHoldingsChange %Shares OutstandingChange %Ownership %Change %Increased PositionsChange %Reduced PositionsChange %
31 Mar, 241614.29%685,866-14.72%8.60%8.46%6-33.33%350.00%
31 Dec, 2314100.00%804,231310413.90%10.09%8995405.66%980.00%2-
30 Sep, 23716.67%259-87.33%0.01%280.46%5150.00%--
30 Jun, 236-45.45%2,044-97.51%0.06%1.01%2-60.00%--
31 Mar, 2311-82,165-29.10%2.47%9.73%5-37.50%--100.00%
31 Dec, 221137.50%115,894-12.90%5.04%15.06%8-2-
30 Sep, 228-133,059-5.78%-8---

InMed Pharmaceuticals Insider Shareholders Trades


Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Feb 22, 2024HULL ANDREWdirector-P-PurchaseBuy37,500$0.39$14.63K38,258
Feb 21, 2024ADAMS ERIC Adirector, officer President & CEOP-PurchaseBuy41,600$0.36$14.92K43,959

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Feb 22, 2024HULL ANDREWdirector-P-PurchaseBuy37,500$0.39$14.63K38,258
Feb 21, 2024ADAMS ERIC Adirector, officer President & CEOP-PurchaseBuy41,600$0.36$14.92K43,959

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Mar 05, 2024HULL ANDREWdirector-H-ExpireLongSell42$307.01$12.89K8,542
Mar 05, 2024HSU ERIC Cofficer Sr. VP, Pre-Clinical Res/DevH-ExpireLongSell309$364.72$112.70K52,545
Mar 05, 2024MANCINI ALEXANDRA DIANE JANETofficer Sr VP, Clinical Reg AffairsH-ExpireLongSell121$312.73$37.84K52,485
Feb 27, 2024Jagpal Nettaofficer Chief Financial OfficerSell50,000$0.37$18.50K-
Dec 06, 2023WOUDENBERG MICHAELofficer Chief Operating OfficerH-ExpireLongSell848$270.36$229.27K10,494
Aug 31, 2023HSU ERIC Cofficer Sr. VP, Pre-Clinical Res/DevH-ExpireLongSell327$499.96$163.49K7,854
May 16, 2023HSU ERIC Cofficer Sr. VP, Pre-Clinical Res/DevH-ExpireLongSell152$623.93$94.84K8,181
May 16, 2023MANCINI ALEXANDRA DIANE JANETofficer Sr VP, Clinical Reg AffairsH-ExpireLongSell485$623.93$302.61K7,606

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Mar 05, 2024HULL ANDREWdirector-H-ExpireLongSell42$307.01$12.89K8,542
Mar 05, 2024HSU ERIC Cofficer Sr. VP, Pre-Clinical Res/DevH-ExpireLongSell309$364.72$112.70K52,545
Mar 05, 2024MANCINI ALEXANDRA DIANE JANETofficer Sr VP, Clinical Reg AffairsH-ExpireLongSell121$312.73$37.84K52,485
Feb 27, 2024Jagpal Nettaofficer Chief Financial OfficerSell50,000$0.37$18.50K-
Feb 22, 2024HULL ANDREWdirector-P-PurchaseBuy37,500$0.39$14.63K38,258
Feb 21, 2024ADAMS ERIC Adirector, officer President & CEOP-PurchaseBuy41,600$0.36$14.92K43,959
Dec 26, 2023Johnson Shane Aaronofficer Sr VP & General ManagerA-AwardBuy40,000$0.37$14.80K48,000
Dec 26, 2023Lemerond Nicoledirector-A-AwardBuy7,100$0.37$2.63K8,500
Dec 26, 2023WOUDENBERG MICHAELofficer Chief Operating OfficerA-AwardBuy65,000$0.37$24.05K75,494
Dec 26, 2023Tegge Jonathanofficer Interim CFOA-AwardBuy30,000$0.37$11.10K31,400
Dec 26, 2023Grove Janet Pdirector-A-AwardBuy7,100$0.37$2.63K8,500
Dec 26, 2023HSU ERIC Cofficer Sr. VP, Pre-Clinical Res/DevA-AwardBuy45,000$0.37$16.65K52,854
Dec 26, 2023ADAMS ERIC Adirector, officer President & CEOA-AwardBuy136,000$0.37$50.32K162,139
Dec 26, 2023Baldasare Bryan Tdirector-A-AwardBuy7,100$0.37$2.63K8,500
Dec 26, 2023MANCINI ALEXANDRA DIANE JANETofficer Sr VP, Clinical Reg AffairsA-AwardBuy45,000$0.37$16.65K52,606
Dec 26, 2023HULL ANDREWdirector-A-AwardBuy7,100$0.37$2.63K8,584
Dec 06, 2023WOUDENBERG MICHAELofficer Chief Operating OfficerH-ExpireLongSell848$270.36$229.27K10,494
Aug 31, 2023HSU ERIC Cofficer Sr. VP, Pre-Clinical Res/DevH-ExpireLongSell327$499.96$163.49K7,854
May 16, 2023HSU ERIC Cofficer Sr. VP, Pre-Clinical Res/DevH-ExpireLongSell152$623.93$94.84K8,181
May 16, 2023MANCINI ALEXANDRA DIANE JANETofficer Sr VP, Clinical Reg AffairsH-ExpireLongSell485$623.93$302.61K7,606

The last insider sell of InMed Pharmaceuticals's stock was made by HULL ANDREW on Mar 05 2024, selling 42 shares at $307.01 per share (valued at $12.89K). The last insider buy of INM was made by HULL ANDREW on Feb 22 2024, buying 37,500 shares at $0.39 per share (worth $14.63K).

InMed Pharmaceuticals Insider Ownership Trends


All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q1 20242450.00%
Q4 20231011000.00%
Q3 2023-1-
Q2 2023-3-
Q1 2023-3-
Q4 2022166266.67%
Q3 20221--
Q2 20222540.00%
Q1 20224944.44%
Q4 2021112550.00%
Q3 20213--
Q4 20201010100.00%
Q1 2020-1-
Q3 2019-1-
Q2 2019-3-
Q1 2019-5-
Q4 2018-1-
Q3 2018-1-
Q2 2018-3-
Q1 2018-3-

2 total buy trades, and 4 total sell trades (buy/sell ratio of 0.50%) were made by InMed Pharmaceuticals's insiders, as of Q1 2024.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q1 20242--
Q4 2023---
Q3 2023---
Q2 2023---
Q1 2023---
Q4 2022---
Q3 2022---
Q2 20222--
Q1 20222--
Q4 20212--
Q3 20213--
Q4 2020---
Q1 2020---
Q3 2019---
Q2 2019---
Q1 2019---
Q4 2018---
Q3 2018---
Q2 2018---
Q1 2018---

As of Q1 2024, Insider owners conducted 2 open market buy trades and 0 open market sell trades of InMed Pharmaceuticals's stocks.

InMed Pharmaceuticals Peer Ownership


TickerCompany
ATNF180 Life Sciences Corp.
ZVSAZyVersa Therapeutics, Inc.
BDRXBiodexa Pharmaceuticals Plc
VRAXVirax Biolabs Group Limited
QNRXQuoin Pharmaceuticals, Ltd.
ICUSeaStar Medical Holding Corporation
PALIPalisade Bio, Inc.
IMMXImmix Biopharma, Inc.
TNXPTonix Pharmaceuticals Holding Corp.
REVBRevelation Biosciences, Inc.
VIRIVirios Therapeutics, Inc.
PHIOPhio Pharmaceuticals Corp.
ALLRAllarity Therapeutics, Inc.
GOVXGeoVax Labs, Inc.
SGTXSigilon Therapeutics, Inc.
SONNSonnet BioTherapeutics Holdings, Inc.
DRUGBright Minds Biosciences Inc.

INM Ownership FAQ


InMed Pharmaceuticals is owned by institutional shareholders (8.60%), insiders (0.58%), and public (90.81%). The largest institutional shareholder of InMed Pharmaceuticals is SABBY MANAGEMENT, LLC (4.54% of total shares) and the top mutual fund owner is FIDELITY CONCORD STREET TRUST (0.00% of total shares).

InMed Pharmaceuticals's major institutional shareholders are SABBY MANAGEMENT, LLC, ARMISTICE CAPITAL, LLC, RENAISSANCE TECHNOLOGIES LLC, TWO SIGMA SECURITIES, LLC, and CITADEL ADVISORS LLC. The top five shareholders own together 8.59% of the company's share outstanding.

As of Mar 2024, there are 16 institutional shareholders of InMed Pharmaceuticals.

SABBY MANAGEMENT, LLC owns 361.73K shares of InMed Pharmaceuticals, representing 4.54% of the company's total shares outstanding, valued at $131.67K (as of Mar 2024).

As of Mar 2024, ARMISTICE CAPITAL, LLC holds 266.97K shares of InMed Pharmaceuticals (INM), compromising 3.35% of the company, valued at $97.18K.

RENAISSANCE TECHNOLOGIES LLC is the third largest holder of InMed Pharmaceuticals. The company owns 28.3K of the company's shares outstanding (worth $10K).